Fulgent Genetics (FLGT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.58
- Estimate
- -$0.44
- Surprise
- -32.2%
- Revenue (period 2026-06-30)
- $85.4M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Fulgent Genetics (FLGT) reported a wider loss than forecast — adjusted EPS of -$0.58 against the -$0.44 estimate (a 32.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates FLGT Sell at 5.0/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -32.2% surprise compares with a +140.8% four-quarter average. Next scheduled report: 2026-11-06.
What argues against it
- Concentration risk — Supplier: Illumina
- Target reached (-21.5% upside)
- Quality below floor (2.4 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.58
- Price target
- $22.32
- Stop
- $19.14
- Upside to target
- +8.5%
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
FLGT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $617.7M
- P/E (fwd)
- -16.3
- 52-week range
- $13.46–$31.04
- Off 52-week high
- 33.7%
- RSI (14)
- 42
- Volume vs avg
- 1.10×
- Score today
- 5.0/10